Retevmo is a type of medicine called a kinase inhibitor, and it blocks the action of RET gene fusions. By blocking RET fusions, Retevmo can help stop cancer cells from growing and spreading.

Rigel Therapeutics expands oncology portfolio with REZLIDHIA & GAVRETO, sees promising R289 results. Click here to read my ...

The US FDA has given accelerated approval for Eli Lilly’s RET inhibitor as a treatment for various RET-altered paediatric cancers, making it the first drug in the class available for children ...

The product, an oral RET inhibitor, was approved in 2020 by the FDA to treat adults with metastatic RET fusion-positive non-small-cell lung cancer (NSCLC), shortly after Roche paid $775 million ...

The review discusses the early trials of multikinase tyrosine kinase inhibitors (TKIs) that were initially used to treat RET-altered thyroid cancer and NSCLC, with limited success. The development ...

It is available for cancer that has been treated before, but not with a RET inhibitor. Selpercatinib is a RET inhibitor. If you are not eligible for selpercatinib but are already having it, you should ...

Targeted therapy for thyroid cancer with BRAF and RET inhibitors has progressed to Phase II clinical trials with first results on the therapeutic response pending. Schematic representation of ...

Lilly’s RETEVMO (selpercatinib) is a highly selective and potent RET kinase inhibitor in locally advanced or metastatic NSCLC. TSO Comprehensive enables broad characterization and simultaneous ...

a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI ...

DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...